The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
Inhibitors
PARP
Resistance
Review
Journal
Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
11
2019
accepted:
23
02
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
18
3
2020
Statut:
epublish
Résumé
Poly(ADP-ribose) polymerase (PARP) inhibitors represent one of the successful novel approaches to targeted cancer treatment. Indeed, the US Food and Drug Administration (FDA) has recently approved PARP inhibitors for the treatment of breast and ovarian cancers. Despite the proven efficacy of these agents, certain challenges remain with their use. Among the most important are primary and secondary resistance. Here, we review the mechanism of action of PARP inhibitors and their ability to exploit certain inherent deficiencies among malignant cells to improve cell killing, with a focus on deficiencies in homologous recombination among cells with
Identifiants
pubmed: 32180937
doi: 10.1186/s13578-020-00390-7
pii: 390
pmc: PMC7065339
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
35Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Lancet Oncol. 2018 Aug;19(8):1126-1134
pubmed: 30026002
Nucleic Acids Res. 2018 Sep 28;46(17):8908-8916
pubmed: 30032250
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
pubmed: 10749912
Mol Cell. 2011 Jan 21;41(2):210-20
pubmed: 21195000
Nat Rev Cancer. 2010 Apr;10(4):293-301
pubmed: 20200537
Nature. 2015 May 28;521(7553):541-544
pubmed: 25799992
J Biol Chem. 2004 Jul 2;279(27):28574-84
pubmed: 15087457
Mol Cancer Res. 2018 Jul;16(7):1092-1102
pubmed: 29592899
Nat Commun. 2017 Aug 29;8(1):374
pubmed: 28851861
Cell Cycle. 2009 Oct 1;8(19):3112-9
pubmed: 19755856
Cancer Discov. 2012 Sep;2(9):798-811
pubmed: 22961666
J Hematol Oncol. 2019 Sep 14;12(1):98
pubmed: 31521196
Clin Cancer Res. 2015 Feb 15;21(4):819-32
pubmed: 25500058
Nat Rev Mol Cell Biol. 2000 Dec;1(3):179-86
pubmed: 11252893
Nature. 2016 Jul 20;535(7612):382-7
pubmed: 27443740
Int J Mol Sci. 2019 May 10;20(9):
pubmed: 31083300
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Science. 2007 May 25;316(5828):1160-6
pubmed: 17525332
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
EMBO J. 2009 Sep 2;28(17):2601-15
pubmed: 19629035
Blood. 2002 Mar 15;99(6):2241-4
pubmed: 11877304
Nat Rev Cancer. 2007 Feb;7(2):95-106
pubmed: 17251916
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Ther Clin Risk Manag. 2018 Nov 02;14:2189-2201
pubmed: 30464492
Sci Signal. 2017 May 23;10(480):
pubmed: 28536297
Clin Cancer Res. 2014 May 1;20(9):2424-32
pubmed: 24583799
Lancet Oncol. 2016 Nov;17(11):1579-1589
pubmed: 27617661
Genes Dev. 2011 Oct 15;25(20):2158-72
pubmed: 22012619
Mol Cell. 2015 Jun 18;58(6):925-34
pubmed: 26091341
Cancer Res. 2011 Aug 15;71(16):5546-57
pubmed: 21742769
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6
pubmed: 24085845
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
Cancer Cell. 2018 Mar 12;33(3):401-416.e8
pubmed: 29533782
Mol Cancer Ther. 2017 Oct;16(10):2058-2068
pubmed: 28655785
N Engl J Med. 2008 Mar 13;358(11):1148-59
pubmed: 18337604
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Annu Rev Med. 2015;66:455-70
pubmed: 25341009
Cancer Discov. 2013 Jan;3(1):68-81
pubmed: 23103855
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Oncotarget. 2015 Sep 29;6(29):28001-10
pubmed: 26334102
Clin Cancer Res. 2017 Aug 15;23(16):4540-4544
pubmed: 28442503
DNA Repair (Amst). 2018 Nov;71:172-176
pubmed: 30177437
Sci Transl Med. 2017 May 31;9(392):
pubmed: 28566428
Cell. 2018 May 3;173(4):972-988.e23
pubmed: 29656893
J Clin Oncol. 2015 Apr 20;33(12):1397-406
pubmed: 25779564
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Nature. 2009 May 21;459(7245):460-3
pubmed: 19357644
Trends Genet. 2019 Feb;35(2):159-172
pubmed: 30595401
Oncogene. 2013 Jun 13;32(24):3001-8
pubmed: 22797065
ACS Nano. 2013 Feb 26;7(2):994-1005
pubmed: 23289892
Nat Struct Mol Biol. 2015 Feb;22(2):150-157
pubmed: 25558984
Cell. 2011 Apr 1;145(1):30-8
pubmed: 21458666
Ann Oncol. 2011 Feb;22(2):268-79
pubmed: 20643861
Lancet Oncol. 2018 Jul;19(7):975-986
pubmed: 29880291
Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28
pubmed: 24579667
Cell Rep. 2016 Jan 26;14(3):429-439
pubmed: 26774475
Invest New Drugs. 2012 Aug;30(4):1493-500
pubmed: 21590367
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Cancer Res. 2014 Jan 1;74(1):287-97
pubmed: 24240700
Leukemia. 2012 Jun;26(6):1266-76
pubmed: 22289989
Cell. 2017 Apr 6;169(2):183
pubmed: 28388401
Annu Rev Biochem. 2010;79:351-79
pubmed: 20533884
Trends Cancer. 2019 Sep;5(9):524-528
pubmed: 31474356
Cancer Discov. 2017 Sep;7(9):984-998
pubmed: 28588062
Sci Transl Med. 2017 Jul 26;9(400):
pubmed: 28747513
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Cancer Manag Res. 2019 May 10;11:4371-4390
pubmed: 31191001
Cell Rep. 2017 Dec 19;21(12):3398-3405
pubmed: 29262321
Int J Pharm. 2013 Aug 16;452(1-2):421-33
pubmed: 23688623
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Cancer Immunol Res. 2015 Nov;3(11):1257-68
pubmed: 26138335
Cancer Cell. 2017 Aug 14;32(2):169-184.e7
pubmed: 28810143
Exp Hematol Oncol. 2019 Nov 11;8:29
pubmed: 31737426
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
Nat Med. 2016 Feb;22(2):194-201
pubmed: 26779812
Cancer Res. 2012 Nov 1;72(21):5547-55
pubmed: 22962264
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
J Clin Oncol. 2019 Sep 1;37(25):2257-2269
pubmed: 31050911
J Natl Cancer Inst. 2015 Nov 27;108(5):
pubmed: 26615020
Cancer Res. 2008 Apr 15;68(8):2581-6
pubmed: 18413725
J Control Release. 2011 May 30;152(1):76-83
pubmed: 21277920
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Nat Commun. 2014 Jul 21;5:4426
pubmed: 25043379
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
pubmed: 18971340
Br J Cancer. 2014 Sep 23;111(7):1319-26
pubmed: 25003660
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Am Soc Clin Oncol Educ Book. 2016;35:298-308
pubmed: 27249709
J Biol Chem. 2014 Mar 28;289(13):9247-53
pubmed: 24554720
Mol Cancer. 2014 Mar 24;13:72
pubmed: 24661910
J Cell Biol. 2011 Aug 22;194(4):567-79
pubmed: 21859861
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Nature. 2008 Feb 28;451(7182):1116-20
pubmed: 18264087
Mol Cancer Ther. 2013 Aug;12(8):1442-52
pubmed: 23699655
Nature. 2018 Aug;560(7716):117-121
pubmed: 30022168
Cell Res. 2008 Jan;18(1):3-7
pubmed: 18157159
Mol Cancer Ther. 2005 Sep;4(9):1364-8
pubmed: 16170028
Clin Cancer Res. 2008 May 15;14(10):2900-8
pubmed: 18483356
J Clin Oncol. 2010 Oct 10;28(29):e563-4; author reply e565-6
pubmed: 20679605
Trends Pharmacol Sci. 2016 Oct;37(10):872-881
pubmed: 27427153
Int J Pharm. 2011 Sep 15;416(1):296-9
pubmed: 21703341
Clin Cancer Res. 2011 May 1;17(9):2799-806
pubmed: 21389100
BMC Med. 2015 Aug 13;13:188
pubmed: 26268938
Cell Rep. 2016 Nov 22;17(9):2367-2381
pubmed: 27880910
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
J Control Release. 2008 Sep 10;130(2):98-106
pubmed: 18534704
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325
Drug Resist Updat. 2012 Feb-Apr;15(1-2):50-61
pubmed: 22464282